Galmed Pharmaceuticals Stock Performance
| GLMD Stock | USD 2.26 0.03 1.31% |
The company retains a Market Volatility (i.e., Beta) of 1.29, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Galmed Pharmaceuticals will likely underperform. At this point, Galmed Pharmaceuticals has a negative expected return of -0.27%. Please make sure to check out Galmed Pharmaceuticals' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Galmed Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Galmed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (1.31) | Five Day Return (6.22) | Year To Date Return (31.93) | Ten Year Return (99.88) | All Time Return (99.91) |
Last Split Factor 1:12 | Last Split Date 2024-08-30 |
1 | Galmed Phar stock hits 52-week low at 2.21 amid challenges By Investing.com - Investing.com South Africa | 02/26/2025 |
2 | Galmed Pharmaceuticals Share Price Passes Below Two Hundred Day Moving Average Heres What Happened - Defense World | 03/12/2025 |
3 | Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks | 03/20/2025 |
| Begin Period Cash Flow | 2.1 M |
Galmed |
Galmed Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 304.00 in Galmed Pharmaceuticals on December 24, 2024 and sell it today you would lose (78.00) from holding Galmed Pharmaceuticals or give up 25.66% of portfolio value over 90 days. Galmed Pharmaceuticals is currently does not generate positive expected returns and assumes 7.2635% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Galmed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Galmed Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galmed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Galmed Pharmaceuticals, and traders can use it to determine the average amount a Galmed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0367
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GLMD |
Estimated Market Risk
| 7.26 actual daily | 64 64% of assets are less volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Galmed Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Galmed Pharmaceuticals by adding Galmed Pharmaceuticals to a well-diversified portfolio.
Galmed Pharmaceuticals Fundamentals Growth
Galmed Stock prices reflect investors' perceptions of the future prospects and financial health of Galmed Pharmaceuticals, and Galmed Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Galmed Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | (8.82 M) | ||||
| Shares Outstanding | 1.66 M | ||||
| Price To Earning | (6.79) X | ||||
| Price To Book | 0.20 X | ||||
| EBITDA | (6.87 M) | ||||
| Net Income | (6.91 M) | ||||
| Cash And Equivalents | 22.4 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 41 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.48 X | ||||
| Book Value Per Share | 12.23 X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Earnings Per Share | 69.72 X | ||||
| Market Capitalization | 3.74 M | ||||
| Total Asset | 16.63 M | ||||
| Retained Earnings | (192.95 M) | ||||
| Working Capital | 10.49 M | ||||
| Current Asset | 23.38 M | ||||
| Current Liabilities | 2.54 M | ||||
About Galmed Pharmaceuticals Performance
By analyzing Galmed Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Galmed Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Galmed Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Galmed Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.1 K | 1.1 K | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | 0.49 | 0.51 | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.57) | (0.54) |
Things to note about Galmed Pharmaceuticals performance evaluation
Checking the ongoing alerts about Galmed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Galmed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Galmed Pharmaceuticals generated a negative expected return over the last 90 days | |
| Galmed Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Latest headline from news.google.com: Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks |
- Analyzing Galmed Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Galmed Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Galmed Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Galmed Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Galmed Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Galmed Pharmaceuticals' stock. These opinions can provide insight into Galmed Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |